Sun Min, Liang Chao, Lin Hui, Chen Zhiyan, Wang Meng, Fang Shijie, Tian Tian, Yang Yujing, Tang Qunzhong, Zhang Erming, Tang Qiang
Department of Cardiology, Peking University Shougang Hospital, Beijing, China.
Heart Center, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Lipids Health Dis. 2024 Jun 12;23(1):185. doi: 10.1186/s12944-024-02170-5.
The atherogenic index of plasma (AIP) is a simple and reliable marker of insulin resistance and is closely associated with various cardiovascular diseases (CVDs). However, the relationships between AIP and left ventricular (LV) geometric indicators have not been adequately assessed. This study was carried out to investigate the association between AIP and LV geometric abnormalities in obstructive sleep apnea (OSA) patients.
This retrospective cross-sectional study included a total of 618 OSA patients (57.3 ± 12.4 years, 73.1% males, BMI 28.1 ± 4.2 kg/m) who underwent echocardiography. Patients with OSA were diagnosed with clinical symptoms and an apnea-hypopnea index ≥ 5.0. LV hypertrophy (LVH) was defined as left ventricular mass index (LVMI) ≥ 50.0 g/m for men and 47.0 g/m for women. AIP was calculated as log (TG/HDL-C).
Compared with the non-LVH group, AIP was significantly higher in the LVH group (0.19 ± 0.29 vs 0.24 ± 0.28, P = 0.024) and the concentric LVH group (0.18 ± 0.29, 0.19 ± 0.30, 0.20 ± 0.26 and 0.29 ± 0.29 in the control, concentric remodeling, eccentric hypertrophy and concentric hypertrophy groups, respectively, P = 0.021). Meanwhile, in the group of patients with the highest AIP tertile, the levels of LVMI (42.8 ± 10.5, 43.2 ± 9.3 and 46.1 ± 12.1 in the T1, T2 and T3 groups, respectively, P = 0.003), and the prevalence of LVH (25.2%, 24.0% and 34.6% in the T1, T2 and T3 groups, respectively, P = 0.032) and concentric LVH (10.7%, 9.8% and 20.2% in the T1, T2 and T3 groups, respectively, P = 0.053) were higher compared with those in the other groups. Positive correlations between AIP and LV geometric indicators including the LVMI, LVMI, LV mass (LVM), diastolic left ventricular inner diameter (LVIDd), diastolic left ventricular posterior wall thickness (PWTd) and diastolic interventricular septal thickness (IVSTd), were revealed according to correlation analysis (P < 0.05). Furthermore, AIP was independently associated with LVMI according to multivariate linear regression model (β = 0.125, P = 0.001). Notably, AIP remained independently associated with an elevated risk of LVH [odds ratio (OR) = 1.317 per 1 standard deviation (SD) increment, 95% confidence interval (CI): 1.058 - 1.639, P = 0.014) and concentric LVH (OR = 1.545 per 1 SD increment, 95% CI: 1.173 - 2.035, P = 0.002) after fully adjusting for all confounding risk factors by multivariate logistic regression analyses.
AIP was independently associated with an increased risk of LVH and concentric LVH in OSA patients. Therefore, AIP, as a practical and cost-effective test, might be useful in monitoring hypertrophic remodeling of the heart and improving CVDs risk stratification in clinical management of OSA.
血浆致动脉粥样硬化指数(AIP)是胰岛素抵抗的一个简单可靠指标,与多种心血管疾病(CVD)密切相关。然而,AIP与左心室(LV)几何指标之间的关系尚未得到充分评估。本研究旨在探讨阻塞性睡眠呼吸暂停(OSA)患者中AIP与LV几何异常之间的关联。
这项回顾性横断面研究共纳入618例接受超声心动图检查的OSA患者(年龄57.3±12.4岁,男性占73.1%,体重指数28.1±4.2kg/m)。OSA患者根据临床症状及呼吸暂停低通气指数≥5.0进行诊断。左心室肥厚(LVH)定义为男性左心室质量指数(LVMI)≥50.0g/m²,女性≥47.0g/m²。AIP计算公式为log(甘油三酯/高密度脂蛋白胆固醇)。
与非LVH组相比,LVH组的AIP显著更高(分别为0.19±0.29和0.24±0.28,P=0.024),同心性LVH组(对照组、同心性重塑组、离心性肥厚组和同心性肥厚组的AIP分别为0.18±0.29、0.19±0.30、0.20±0.26和0.29±0.29,P=0.021)。同时,在AIP三分位数最高的患者组中,LVMI水平(T1、T2和T3组分别为42.8±10.5、43.2±9.3和46.1±12.1,P=0.003)、LVH患病率(T1、T2和T3组分别为25.2%、24.0%和34.6%,P=0.032)和同心性LVH患病率(T1、T2和T3组分别为10.7%、9.8%和20.2%,P=0.053)均高于其他组。相关性分析显示,AIP与LV几何指标包括LVMI、左心室质量(LVM)、舒张末期左心室内径(LVIDd)、舒张末期左心室后壁厚度(PWTd)和舒张末期室间隔厚度(IVSTd)之间存在正相关(P<0.05)。此外,根据多变量线性回归模型,AIP与LVMI独立相关(β=0.125,P=0.001)。值得注意的是,在通过多变量逻辑回归分析对所有混杂风险因素进行充分校正后,AIP与LVH风险升高[每增加1个标准差(SD)的比值比(OR)=1.317,95%置信区间(CI):1.058 - 1.639,P=0.014]和同心性LVH(每增加1个SD的OR=1.545,95%CI:1.173 - 2.035,P=0.002)仍独立相关。
AIP与OSA患者LVH和同心性LVH风险增加独立相关。因此,AIP作为一种实用且经济有效的检测方法,可能有助于监测心脏肥厚性重塑,并改善OSA临床管理中的CVD风险分层。